Risk factors for red blood cell alloimmunization in patients with hematologic malignancy
Transfusion Medicine · 2024
DOI: 10.1111/tme.13096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion Medicine, 2024. Verfasst von Pakthipa Pattarakosol und 3 weiteren Autor:innen. Beteiligte Einrichtung: Transfusion Medicine Unit, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. Hauptthemen laut MEDLINE: Isoantibodies, Erythrocytes, Hematologic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Introduction
Patients with hematologic malignancy have a higher risk of developing red blood cell (RBC) alloimmunization which can delay blood transfusion. Information on the risk factors for alloimmunization in this group is still limited. This study aimed to determine the prevalence and predictors of RBC alloimmunization among these patients. Materials and Methods Electronic medical records of the patients with acute myeloid leukaemia (AML), acute lymphoid leukaemia (ALL), multiple myeloma (MM) and lymphoma from a tertiary care hospital between January 2018 and December 2022 were retrospectively reviewed. Clinical, demographic and transfusion history data of the included patients were analysed.
Results
Of the 983 patients with hematologic malignancy, 798 were included in the study. The prevalence of RBC alloantibodies in this population was 4.8% (38 patients). The alloimmunization rate of each subgroup was as followed: AML 9.1%, ALL 2.9%, MM 3.8% and lymphoma 2.5%. The most common alloantibodies were anti‐Mi a , anti‐E and anti‐Le a . The majority (29/38, 76.3%) of alloimmunization had a single alloantibody. RBC autoantibody was detected in 10 patients. The detection of autoantibodies and having AML were independently associated with RBC alloimmunization (adjusted odds ratio [aOR] 13.41, 95% confidence interval [CI] 2.00–89.72, p = 0.007 and aOR 11.44, 95% CI 2.02–64.72, p = 0.006, respectively).
Conclusion
The prevalence of RBC alloimmunization in the patients with hematologic malignancy was 4.8%. The alloimmunization rate of the AML subgroup was higher than those of other hematologic malignancies. The detection of autoantibodies and the AML diagnosis were identified as potential risk factors for RBC alloimmunization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Transfusion Medicine Unit, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
- Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Hematology unit, Department of Medicine, Chulabhorn Hospital, Bangkok, Thailand.
- Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
ORCID-Profile: Phandee Watanaboonyongcharoen, Ponlapat Rojnuckarin
Zitieren
APA
Pattarakosol, P., Lorucharoen, N., Watanaboonyongcharoen, P., & Rojnuckarin, P. (2024). Risk factors for red blood cell alloimmunization in patients with hematologic malignancy. Transfusion Medicine. https://doi.org/10.1111/tme.13096
Vancouver
Pattarakosol P, Lorucharoen N, Watanaboonyongcharoen P, Rojnuckarin P. Risk factors for red blood cell alloimmunization in patients with hematologic malignancy. Transfusion Medicine. 2024. doi:10.1111/tme.13096
BibTeX
@article{Pattarakosol2024,
author = {Pattarakosol, Pakthipa and Lorucharoen, Nattarat and Watanaboonyongcharoen, Phandee and Rojnuckarin, Ponlapat},
title = {Risk factors for red blood cell alloimmunization in patients with hematologic malignancy},
journal = {Transfusion Medicine},
year = {2024},
doi = {10.1111/tme.13096}
}
EUVIMED